Therex LLC, is a company formed by three UB faculty members, utilizing patents and technologies based on their prior research with salicylanilide chemical compounds and licesed fromthe university. Further research with the compounds as a potential active ingredient in personal-care, pharmaceutical and animal-care products through Therex LLC may lead to new anti-inflammatory and anti-microbial drug products for the treatment of oral, gastrointestinal and skin diseases. The primary goal of Therex LLC is to co-develop, with large pharmaceutical companies, new generations of similar drugs targeted to infections and inflammatory diseases that affect mucous membranes and skinTherex LLC is a biotechnology company that discovers and develops improved products for the oral and dermal health care markets. Therex utilizes its proprietary and patented drug platform technology, i.e., topically active drugs that posses both antibacterial and anti-inflammatory activities, to produce safer and more effective treatments for oral and skin conditions with large markets and unmet needs. These conditions include gingivitis and resultant periodontal disease, acne, and chronic skin wounds such as those found in diabetic ulcers, bed sores and severe burns. Therexs lead drug candidate, Naphthafluor, is currently in development as a treatment for gingivitis and acne supported, in part, with funds from the National Institutes of Health (NIH) through its Small Business Innovative Research (SBIR) programs and from its strategic partner, a Fortune 500 U.S. based oral and personal care product company
